搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Allure on MSN
1 天
Everything You Need to Know About the 2024 RSV Season
Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...
6 天
IDWeek 2024丨儿童RSV预防:疫苗与单抗临床研究进展
编者按:呼吸道合胞病毒(RSV)作为一种对婴幼儿及免疫功能不全人群构成重大威胁的呼吸道病原体,近年来其疫苗和单克隆抗体的研发取得了诸多进展。在刚结束的2024年美国感染性疾病周(IDWeek 2024)上,多项关于儿童RSV防治的最新研究成果备受瞩目 ...
FiercePharma
2 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
来自MSN
1 天
Is It the Flu, COVID, RSV or Allergies? Here Are Easy Ways to Tell
Besides the flu, other respiratory viruses such as respiratory syncytial virus (RSV) and COVID also tend to peak during the ...
4 天
on MSN
辉瑞制药:RSV 疫苗获美 FDA 批准
【10 月 23 日电,辉瑞制药 RSV 疫苗获 FDA 批准】 辉瑞制药针对呼吸道合胞体病毒的疫苗已获得美国食品药品管理局(FDA)批准。该疫苗用于 18 - 59 岁年龄段人群接种。
4 天
辉瑞(PFE.US)RSV疫苗获FDA批准用于18-59岁年龄段人群接种
智通财经获悉,美国食品药品监督管理局(FDA)已批准辉瑞公司(PFE.US)的呼吸道合胞病毒(RSV)疫苗Abrysvo用于18至59岁下呼吸道疾病风险增加的人群。这些疾病包括肥胖、糖尿病、慢性阻塞性肺病、心力衰竭、慢性肾病和哮喘。扩大批准是基于3期 ...
FiercePharma
1 天
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
4 天
FDA批准辉瑞制药公司的RSV疫苗扩大使用范围至50岁以下成年人
纽约 - 辉瑞制药公司(NYSE: ...
4 天
on MSN
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Medpage Today on MSN
6 天
RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...
MedPage Today on MSN
3 天
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
4 天
on MSN
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈